Neuronetics to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call

Rhea-AI Summary

Neuronetics, based in Malvern, PA, announced it will release its second quarter financial and operational results on August 3, 2021, before the market opens. A conference call will follow at 8:30 a.m. ET to discuss the results. Investors can listen via a webcast on Neuronetics' investor relations site or by dialing in using a provided telephone number and confirmation code. The company specializes in medical technology aimed at improving the quality of life for patients with psychiatric disorders, notably through its FDA-cleared NeuroStar® Advanced Therapy System.

MALVERN, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release second quarter financial and operating results prior to market open on Tuesday, August 3, 2021. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

The conference call will be broadcast live in listen-only mode via a webcast on the Company’s investor relations website at ir.neuronetics.com. To listen to the conference call on your telephone, please dial (877) 472-8990 for United States callers or +1 (629) 228-0778 for international callers and reference confirmation code 8826628, approximately ten minutes prior to start time. The replay will be available on the Company's website for approximately 60 days.

About Neuronetics

Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Additional information can be found at www.neuronetics.com.

Investor Contact:

Mike Vallie or Mark Klausner
Westwicke Partners
443-213-0499
ir@neuronetics.com

Media Contact:

Chelsey Manko
Vault Communications
610-455-2778
cmanko@vaultcommunications.com

FAQ

When will Neuronetics release its second quarter results for 2021?

Neuronetics will release its second quarter results on August 3, 2021, before market open.

What time is the Neuronetics conference call scheduled for?

The conference call is scheduled for 8:30 a.m. Eastern Time on August 3, 2021.

How can I listen to the Neuronetics conference call?

You can listen to the conference call via webcast on Neuronetics' investor relations website or by dialing (877) 472-8990 in the U.S.

What technology does Neuronetics specialize in?

Neuronetics specializes in medical technology for psychiatric disorders, particularly through its NeuroStar® Advanced Therapy System.

Is NeuroStar® cleared by the FDA?

Yes, the NeuroStar® Advanced Therapy System is FDA-cleared for treating major depressive disorder.